In CheckMate-498, a randomized clinical trial, nivolumab combined with bevacizumab and nivolumab combined with chemoradiotherapy in newly diagnosed glioma patients with O6-methylguanine DNA methyltransferase (MGMT) promoter unmethylation were both ineffective (Reardon et al., 2020). This evidence concerns the gene MGMT and central nervous system cancer.